GLP-1 receptor agonists and twin agonists have reworked the therapy of weight problems and different metabolic ailments, and a brand new editorial co-authored by Dr. Steven Heymsfield of LSU’s Pennington Biomedical Analysis Middle and Dr. Adam Gilden of the College of Colorado examines what scientists are studying as these drugs attain hundreds of thousands of individuals.
The editorial, “Unanticipated Effects of GLP-1 Receptor Agonists: A Net Positive,” was revealed within the journal Weight problems and highlights further advantages that weren’t totally anticipated when the medication have been initially developed.
“Many of the unanticipated negative effects of GLP-1 receptor agonists have been optimistic,” the authors wrote.
The researchers spotlight proof suggesting GLP-1 drugs could scale back irritation and decrease the chance of sure cardiovascular and musculoskeletal circumstances. Rising research additionally recommend the drugs could scale back alcohol consumption and the chance of sure substance use issues, though further scientific trials are wanted to substantiate these results.
On the identical time, questions stay in regards to the drugs’ results on lean physique mass and dietary well being. Weight reduction related to GLP-1 drugs can embody reductions in lean mass, together with muscle, making it vital to know tips on how to protect muscle via train and applicable vitamin. Decreased urge for food may enhance the chance of micronutrient deficiencies in some sufferers.
“GLP-1 receptor agonists have already reworked the follow of medication in the US, and this modification will proceed as extra drugs come onto the market,” the authors wrote.
The researchers determine three key priorities for future GLP-1 analysis:
- Understanding the mechanisms behind potential reductions in irritation,
- Conducting randomized trials to raised perceive adjustments in lean physique mass and methods to protect muscle,
- Conducting bigger randomized trials to find out whether or not these drugs can scale back alcohol use issues.
Regardless of the remaining questions, the authors conclude that the proof accessible thus far helps a positive total risk-benefit profile for GLP-1 receptor agonists and twin agonists.
Reference: Gilden AH, Heymsfield SB. Unanticipated results of GLP -1 receptor agonists: a web optimistic. Weight problems. 2026:oby.70288. doi: 10.1002/oby.70288
This text has been republished from the next materials. Be aware: materials could have been edited for size and content material. For additional data, please contact the cited supply. Our press launch publishing coverage could be accessed here.
